comparemela.com

Biotechnology company Rocket Pharmaceuticals, Inc. (RCKT) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to RP-A601, the Company's gene therapy candidate for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM).

Related Keywords

Spain , ,Gamestop Corp ,Exchange Commission ,Us Consumer Product Safety Commission ,Boppy Co ,Chairman Ryan Cohen ,Executive Chairman ,Matthew Furlong ,Chief Executive Officer ,Product Safety Commission ,Boppy Newborn Loungers ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.